EDX Medical launches comprehensive hereditary germline cancer tests in the UK, covering 70 cancer-linked genes.
EDX Medical, a cancer diagnostics firm, expands its cancer testing capability with new comprehensive hereditary germline cancer testing products. The new tests, set to launch in the UK, will identify mutations in 70 genes linked to cancers with strong inherited components, including prostate, breast, colorectal, pancreatic, and ovarian cancers. The first test achieves 99% sensitivity and will be available to health professionals.
June 20, 2024
3 Articles